Insider selling is routine, small-scale, and follows normal option-exercise patterns — no bearish signal. The broader cluster (13 trades, 7 insiders) is also immaterial at 0.07% of market cap. No short-term action warranted. Monitor next quarterly results for pipeline catalysts, as the 95% bullish analyst consensus and strong institutional ownership (Fidelity, BlackRock) reflect optimism about the drug development pipeline.
Price Chart
Executive Summary
Two ORKA insiders — a director and the SVP of Finance — sold $1.01M in open-market shares ($882K of that from director Carl Dambkowski alone) in the past week. However, this selling is dwarfed by a much larger, broader cluster spanning 13 trades by 7 insiders in a 7-day window ending June 15 (including the CEO, CMO, COO, and GC), which includes non-cash derivative exercises and follow-on open-market sales. The aggregate open-market selling of ~$2.9M represents only ~0.07% of market cap and is largely consistent with routine post-vesting liquidity sales following recent option exercises, not a bearish informed signal.
Key Financial Metrics
Key Facts
- Two-insider cluster (Director, SVP Finance) sold ~$1.01M open-market over June 5-12.
- Broader 7-day window includes 13 trades by 7 insiders (CEO, CMO, COO, GC, Director, SVP Finance, other) with $2.9M in open-market sales.
- Director Carl Dambkowski alone sold 35K shares for ~$2.45M (the dominant seller).
- CEO Klein sold $120K, CMO Goncalves sold $112K, COO Sandler sold $42K, GC Quinlan sold $51K.
- Multiple non-cash derivative exercises (options exercised at $0 or $6.84) preceded open-market sales, consistent with sell-to-cover / cashless exercise patterns.
- Total cluster open-market sales ~$2.9M at a $4.2B market cap = only 0.07% of market cap.
- Recent 30-day insider activity (6 sells totaling $480K) matches this pattern — persistent but tiny relative to company size.
- Analyst consensus is 95% bullish (19 Buy, 1 Hold); top holders include Fidelity, BlackRock, and RTW Investments.
Financial Impact
Total open-market sales of ~$2.9M represent approximately 0.07% of $4.2B market cap, a trivial amount.
Risk Factors
- Director Dambkowski sold ~$2.45M aggressively over three days — largest insider seller; worth watching if pattern continues.
- Pre-revenue biopharma risk: stock is driven by clinical data, not insider activity at these trivial levels.
- Historical calibration shows go-long calls on ORKA have underperformed (avg T+20 alpha -0.94%), and the score-6/7/8 cells have net-negative expected alpha.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ORKA-1781564346347 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $84.38 (−9.80%) |
Sep 1, 2026 4w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $84.38 (+7.91%) |
Aug 28, 2026 5w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $84.38 (+7.42%) |
Aug 17, 2026 6w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $84.38 (−25.38%) |
Aug 10, 2026 7w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 10, 2026 7w ago | 8-K | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 9, 2026 7w ago | Institutional Cluster | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Jul 15, 2026 11w ago | Insider Cluster | $83.04 $91.95 | ▲ +10.73% | ▲ +12.40% | $84.38 (+1.61%) |
Jul 2, 2026 13w ago | Insider Cluster | $85.21 $88.27 | ▲ +3.59% | ▲ +2.66% | $84.38 (−0.97%) |
Jun 22, 2026 14w ago | Insider Cluster | $83.40 $92.49 | ▲ +10.90% | ▲ +9.89% | $84.38 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access